KR20110071139A - Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드 - Google Patents

Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드 Download PDF

Info

Publication number
KR20110071139A
KR20110071139A KR1020117011399A KR20117011399A KR20110071139A KR 20110071139 A KR20110071139 A KR 20110071139A KR 1020117011399 A KR1020117011399 A KR 1020117011399A KR 20117011399 A KR20117011399 A KR 20117011399A KR 20110071139 A KR20110071139 A KR 20110071139A
Authority
KR
South Korea
Prior art keywords
lip1
seq
ser
sign
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117011399A
Other languages
English (en)
Korean (ko)
Inventor
루돌프 마리아 데 빌트
Original Assignee
도만티스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도만티스 리미티드 filed Critical 도만티스 리미티드
Publication of KR20110071139A publication Critical patent/KR20110071139A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020117011399A 2008-10-21 2009-10-19 Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드 Withdrawn KR20110071139A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
US61/107,085 2008-10-21

Publications (1)

Publication Number Publication Date
KR20110071139A true KR20110071139A (ko) 2011-06-28

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117011399A Withdrawn KR20110071139A (ko) 2008-10-21 2009-10-19 Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드

Country Status (16)

Country Link
US (1) US20110257373A1 (https=)
EP (1) EP2356149A2 (https=)
JP (1) JP2012506237A (https=)
KR (1) KR20110071139A (https=)
CN (1) CN102257009A (https=)
AR (1) AR073905A1 (https=)
AU (1) AU2009306424A1 (https=)
BR (1) BRPI0919714A2 (https=)
CA (1) CA2740856A1 (https=)
EA (1) EA201100488A1 (https=)
IL (1) IL212086A0 (https=)
MX (1) MX2011004244A (https=)
TW (1) TW201019962A (https=)
UY (1) UY32189A (https=)
WO (1) WO2010046337A2 (https=)
ZA (1) ZA201102763B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046338A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Composition for targeting dendritic cells
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
DE602004025711D1 (de) * 2003-08-21 2010-04-08 Lipotek Pty Ltd In vivo targeting von dendritischen zellen
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2601115A1 (en) * 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
AU2007300543A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
AU2009306424A1 (en) 2010-04-29
WO2010046337A2 (en) 2010-04-29
BRPI0919714A2 (pt) 2015-12-08
AR073905A1 (es) 2010-12-09
TW201019962A (en) 2010-06-01
WO2010046337A3 (en) 2010-07-01
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CA2740856A1 (en) 2010-04-29
JP2012506237A (ja) 2012-03-15
UY32189A (es) 2010-05-31
EP2356149A2 (en) 2011-08-17
CN102257009A (zh) 2011-11-23
ZA201102763B (en) 2012-09-26
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25

Similar Documents

Publication Publication Date Title
CN111647082B (zh) 抗人il-4ra的抗体及其用途
CN110396129B (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
CN115109156B (zh) 一种靶向bcma的纳米抗体及其应用
CA3128104A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
KR20120101417A (ko) 안정한 항?ｔｎｆｒ1 폴리펩티드，항체 가변 도메인 및 길항제
CN114835802B (zh) 针对呼吸道合胞病毒的蛋白结合分子
WO2023208104A1 (zh) 抗人il-4ra的抗体及其用途
JP2022528230A (ja) Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
KR20110071139A (ko) Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
CA3192254A1 (en) Antibody specifically bound to glycosylated ceacam5
CN118576543A (zh) 一种结合人CD3/IL13Rα的双特异性抗体制剂及其应用
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
WO2025228370A1 (zh) 中和呼吸道合胞病毒的抗原结合蛋白及其应用
WO2024217575A1 (zh) 一种抗pd-l1纳米抗体及其制备方法和应用
CN121005782A (zh) ActRIIB结合分子及其应用
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
CN120904325A (zh) 靶向ActRIIB的纳米抗体及其应用
CN121181695A (zh) ActRIIB抗原结合蛋白及其应用
HK40127090A (zh) 表皮生长因子受体变体iii抗体
CN119775409A (zh) 靶向sost的抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid